Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation..
BACKGROUND AND AIMS: We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD].
METHODS: We conducted a prospective study including 213 IBD patients and 53 healthy controls: 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab, or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination, and interval between vaccination and sampling.
RESULTS: Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (geometric mean ratio 0.35 [95% confidence interval 0.20-0.60], p = 0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p = 0.0050), and tofacitinib (0.28 [0.14-0.57], p = 0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p = 0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p = 0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p = 0.017), and tofacitinib (0.23 [0.10-0.56], p = 0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 [r = 0.27; p = 0.0004] and H1N1 [r = 0.33; p < 0.0001].
CONCLUSIONS: Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to influenza/A, similar to COVID-19 vaccine-induced antibody responses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 18(2024), 4 vom: 23. Apr., Seite 560-569 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
87LA6FU830 |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjad182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364331747 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364331747 | ||
| 003 | DE-627 | ||
| 005 | 20240426233352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjad182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM364331747 | ||
| 035 | |a (NLM)37941436 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Zhigang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. | ||
| 520 | |a BACKGROUND AND AIMS: We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with inflammatory bowel disease [IBD] | ||
| 520 | |a METHODS: We conducted a prospective study including 213 IBD patients and 53 healthy controls: 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab, or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination, and interval between vaccination and sampling | ||
| 520 | |a RESULTS: Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (geometric mean ratio 0.35 [95% confidence interval 0.20-0.60], p = 0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p = 0.0050), and tofacitinib (0.28 [0.14-0.57], p = 0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p = 0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p = 0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p = 0.017), and tofacitinib (0.23 [0.10-0.56], p = 0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 [r = 0.27; p = 0.0004] and H1N1 [r = 0.33; p < 0.0001] | ||
| 520 | |a CONCLUSIONS: Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to influenza/A, similar to COVID-19 vaccine-induced antibody responses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a JAK-inhibitor | |
| 650 | 4 | |a anti-TNF | |
| 650 | 4 | |a humoral immunity | |
| 650 | 4 | |a immunisation | |
| 650 | 7 | |a tofacitinib |2 NLM | |
| 650 | 7 | |a 87LA6FU830 |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Alexander, James L |e verfasserin |4 aut | |
| 700 | 1 | |a Yee Eng, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Ibraheim, Hajir |e verfasserin |4 aut | |
| 700 | 1 | |a Anandabaskaran, Sulak |e verfasserin |4 aut | |
| 700 | 1 | |a Saifuddin, Aamir |e verfasserin |4 aut | |
| 700 | 1 | |a Constable, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Castro Seoane, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Bewshea, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Nice, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a D'Mello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Gareth R |e verfasserin |4 aut | |
| 700 | 1 | |a Balarajah, Sharmili |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorentino, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastian, Shaji |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, Peter M |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Lucy C |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Horace R T |e verfasserin |4 aut | |
| 700 | 1 | |a Kent, Alexandra J |e verfasserin |4 aut | |
| 700 | 1 | |a Linger, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Parkes, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Kok, Klaartje |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Kamal V |e verfasserin |4 aut | |
| 700 | 1 | |a Teare, Julian P |e verfasserin |4 aut | |
| 700 | 1 | |a Altmann, Daniel M |e verfasserin |4 aut | |
| 700 | 1 | |a Boyton, Rosemary J |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, Ailsa L |e verfasserin |4 aut | |
| 700 | 1 | |a Lees, Charlie W |e verfasserin |4 aut | |
| 700 | 1 | |a Goodhand, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Nicholas A |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Katrina M |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Tariq |e verfasserin |4 aut | |
| 700 | 1 | |a Powell, Nick |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 18(2024), 4 vom: 23. Apr., Seite 560-569 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:4 |g day:23 |g month:04 |g pages:560-569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjad182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 4 |b 23 |c 04 |h 560-569 | ||